AstraZeneca (AZN)’s Lung Drug Delivers the Good News its Pipeline Needed

On September 8, 2026, CNBC announced that AstraZeneca PLC (NYSE:AZN) had completed two successful late-stage trials of tozorakimab, a potential new drug for chronic obstructive pulmonary disease (COPD). The results demonstrated the drug reduced moderate and severe flare-ups by approximately 30% across a wide range of patients, validating the company's forecast of peak annual sales exceeding $5 billion.

AstraZeneca has applied for FDA priority review, anticipating a decision in the first quarter of 2027. The biologic targets the inflammatory protein IL-33, potentially reaching a larger patient population than current biologics which only target high eosinophil levels. The trials revealed that tozorakimab reduced COPD exacerbations by 29% to 34%, regardless of eosinophil levels, smoking status, or disease severity.

This broad efficacy may provide AstraZeneca with access to patient groups currently overlooked by competing biologics such as Regeneron's Dupixent and Sanofi's Nucala. The drug's potential to address a broader COPD patient base could position AstraZeneca to tap into a larger market, supporting their goal of reaching $80 billion in annual revenue by 2030.

However, the drug faces regulatory hurdles and needs to prove its advantage over established COPD treatments. While the trials demonstrated the drug's efficacy, they did not directly compare tozorakimab with existing biologics like Dupixent or Nucala. AstraZeneca must demonstrate how physicians should integrate the drug into treatment protocols, particularly for higher-eosinophil patients who already have established biologic options.

Even if approved, the drug will require years to establish a substantial commercial presence and achieve its projected sales ceiling. In the meantime, AstraZeneca must navigate patent expiration issues on its current medicines, such as Farxiga and Brilinta, which could impact short-term revenue growth. Despite these challenges, tozorakimab represents a significant opportunity for AstraZeneca's long-term growth strategy.